BG64278B1 - 2--ианиминоимидазолови производни, 'ъ''ав, м...'оди за пол"-аван...'о им и 'яхно'о използван... - Google Patents

2--ианиминоимидазолови производни, 'ъ''ав, м...'оди за пол"-аван...'о им и 'яхно'о използван... Download PDF

Info

Publication number
BG64278B1
BG64278B1 BG103220A BG10322099A BG64278B1 BG 64278 B1 BG64278 B1 BG 64278B1 BG 103220 A BG103220 A BG 103220A BG 10322099 A BG10322099 A BG 10322099A BG 64278 B1 BG64278 B1 BG 64278B1
Authority
BG
Bulgaria
Prior art keywords
alkyl
substituted
formula
hydrogen
aryl
Prior art date
Application number
BG103220A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG103220A (en
Inventor
Eddy J. Freyne
Francisco J. Fernandez-Gadea
Jose I. Andres-Gil
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG103220A publication Critical patent/BG103220A/xx
Publication of BG64278B1 publication Critical patent/BG64278B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BG103220A 1996-10-02 1999-03-01 2--ианиминоимидазолови производни, 'ъ''ав, м...'оди за пол"-аван...'о им и 'яхно'о използван... BG64278B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96202749 1996-10-02
PCT/EP1997/005322 WO1998014432A1 (en) 1996-10-02 1997-09-24 Pde iv inhibiting 2-cyanoiminoimidazole derivatives

Publications (2)

Publication Number Publication Date
BG103220A BG103220A (en) 1999-11-30
BG64278B1 true BG64278B1 (bg) 2004-08-31

Family

ID=8224456

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103220A BG64278B1 (bg) 1996-10-02 1999-03-01 2--ианиминоимидазолови производни, 'ъ''ав, м...'оди за пол"-аван...'о им и 'яхно'о използван...

Country Status (30)

Country Link
US (1) US6051718A (cs)
EP (1) EP0934280B1 (cs)
JP (1) JP3068208B2 (cs)
KR (1) KR100520002B1 (cs)
CN (1) CN1106387C (cs)
AR (1) AR008875A1 (cs)
AT (1) ATE236884T1 (cs)
AU (1) AU719561B2 (cs)
BG (1) BG64278B1 (cs)
BR (1) BR9712256B1 (cs)
CA (1) CA2267322C (cs)
CY (1) CY2380B1 (cs)
CZ (1) CZ297474B6 (cs)
DE (1) DE69720757T2 (cs)
DK (1) DK0934280T3 (cs)
EE (1) EE03825B1 (cs)
ES (1) ES2196308T3 (cs)
HU (1) HU225158B1 (cs)
IL (2) IL129298A0 (cs)
MY (1) MY116980A (cs)
NO (1) NO312960B1 (cs)
NZ (1) NZ334971A (cs)
PL (1) PL194673B1 (cs)
PT (1) PT934280E (cs)
RU (1) RU2180902C2 (cs)
SI (1) SI0934280T1 (cs)
SK (1) SK285878B6 (cs)
TR (1) TR199900732T2 (cs)
UA (1) UA62939C2 (cs)
WO (1) WO1998014432A1 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284468B6 (sk) 1998-04-01 2005-04-01 Janssen Pharmaceutica N. V. Pyridínový derivát, spôsob jeho prípravy a použitie, kompozícia s jeho obsahom a spôsob jej prípravy
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
NZ528820A (en) 2001-04-19 2007-01-26 Eisai Co Ltd 2-iminopyrrolidine derivatives
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
US20040220227A1 (en) * 2001-07-11 2004-11-04 Shinji Ina Remedies for allergic eye diseases
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
US7507707B2 (en) 2001-12-14 2009-03-24 Laboratoires Serono Sa Methods of inducing ovulation using a non-polypeptide camp level modulator
EP2444393A1 (en) * 2003-02-19 2012-04-25 Eisai R&D Management Co., Ltd. Methods for producing cyclic benzamidine derivatives
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3409666A3 (en) * 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
GB2533925A (en) * 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784461B2 (ja) * 1986-12-19 1995-09-13 日本バイエルアグロケム株式会社 殺虫性ニトロイミノ又はシアノイミノ化合物
JPH05310650A (ja) * 1991-08-22 1993-11-22 Nippon Soda Co Ltd 新規なアミン誘導体、その製造方法及び殺虫剤
CZ14795A3 (en) * 1992-07-28 1996-07-17 Rhone Poulenc Rorer Ltd Benzene derivative containing phenyl group bound to aryl or heteroaryl fraction through an aliphatic or hetero atom containing group, process of its preparation and pharmaceutical composition containing thereof
NZ257955A (en) * 1992-12-02 1996-05-28 Pfizer Catechol diethers pharmaceutical compositions
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
JP3775685B2 (ja) * 1993-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド Ｐｄｅ▲ｉｖ▼およびｔｎｆ抑制剤としての化合物
EP0714397A1 (en) * 1993-08-19 1996-06-05 Smithkline Beecham Corporation Phenethylamine compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
CA2193725A1 (en) * 1994-06-24 1996-01-04 David Cavalla Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
JP2000503678A (ja) 2000-03-28
MY116980A (en) 2004-04-30
PL332573A1 (en) 1999-09-27
EE03825B1 (et) 2002-08-15
HK1020344A1 (en) 2000-04-14
HU225158B1 (en) 2006-07-28
PL194673B1 (pl) 2007-06-29
EP0934280A1 (en) 1999-08-11
HUP9904063A3 (en) 2000-11-28
SI0934280T1 (en) 2003-12-31
CA2267322A1 (en) 1998-04-09
DE69720757T2 (de) 2004-03-04
NO312960B1 (no) 2002-07-22
ES2196308T3 (es) 2003-12-16
IL129298A (en) 2006-04-10
JP3068208B2 (ja) 2000-07-24
AR008875A1 (es) 2000-02-23
NZ334971A (en) 2000-09-29
KR100520002B1 (ko) 2005-10-13
US6051718A (en) 2000-04-18
BR9712256A (pt) 1999-08-24
KR20000029964A (ko) 2000-05-25
TR199900732T2 (xx) 1999-08-23
AU4779297A (en) 1998-04-24
NO991560D0 (no) 1999-03-30
CA2267322C (en) 2007-11-06
DE69720757D1 (de) 2003-05-15
EP0934280B1 (en) 2003-04-09
WO1998014432A1 (en) 1998-04-09
CN1106387C (zh) 2003-04-23
CN1232456A (zh) 1999-10-20
CZ102899A3 (cs) 1999-07-14
DK0934280T3 (da) 2003-07-21
RU2180902C2 (ru) 2002-03-27
ATE236884T1 (de) 2003-04-15
CY2380B1 (en) 2004-06-04
NO991560L (no) 1999-06-02
UA62939C2 (uk) 2004-01-15
EE9900112A (et) 1999-10-15
BR9712256B1 (pt) 2011-04-19
PT934280E (pt) 2003-08-29
HUP9904063A2 (hu) 2000-09-28
SK34499A3 (en) 2000-04-10
AU719561B2 (en) 2000-05-11
BG103220A (en) 1999-11-30
IL129298A0 (en) 2000-02-17
CZ297474B6 (cs) 2006-12-13
SK285878B6 (sk) 2007-10-04

Similar Documents

Publication Publication Date Title
BG64278B1 (bg) 2--ианиминоимидазолови производни, 'ъ''ав, м...'оди за пол"-аван...'о им и 'яхно'о използван...
HU223324B1 (hu) 1,3-Dihidro-1-(fenil-alkil)-2H-imidazol-2-on származékok alkalmazása PDE IV és citokin hatású gyógyszerkészítmények előállítására, új 1,3-dihidro-1-(fenil-alkil)-2H-imidazol-2-on-származékok, eljárás előállításukra és ezeket tartalmazó ...
KR19980703450A (ko) Pde iv 및 사이토킨 억제 활성을 가진 1,3-디하이드로-1-(페닐알케닐)-2h-이미다졸-2-온 유도체
JP4778612B2 (ja) Ｐｄｅｉｖ阻害ピリジン誘導体
KR100400159B1 (ko) Pdeiv및사이토킨억제활성을가진1,3-디하이드로-2h-이미다졸-2-온유도체
HK1020344B (en) Pde iv inhibiting 2-cyanoiminoimidazole derivatives
MXPA00009632A (en) Pde iv inhibiting pyridine derivatives
HK1033579B (en) Pde iv inhibiting pyridine derivatives